James Loerop's Insider Trades & SAST Disclosures
James Loerop's most recent trade in Aclaris Therapeutics Inc was a trade of 292,300 Employee Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern James Loerop.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 292,300 | 292,300 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2025 | 83,500 | 83,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 01 Feb 2025 | 15,447 | 103,306 (0%) | 0% | 2.5 | 38,309 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 44,250 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 14,750 | 118,753 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 11,250 | 96,503 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 11,250 | 11,250 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 104,003 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2025 | 7,500 | 15,000 | - | - | Resticted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 107,767 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 73,750 | 73,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 55,000 | 55,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 32,089 | 75,678 (0%) | 0% | 2.5 | 79,581 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 18,150 | 36,850 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 18,150 | 93,828 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 31 Dec 2024 | 8,575 | 85,253 (0%) | 0% | 2.5 | 21,266 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 206,500 | 206,500 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 147,500 | 147,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 11,250 | 32,938 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 11,250 | 22,500 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 36,585 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,500 | 22,500 | - | - | Restricted Stock Unit | |
| Aclaris Therapeutics Inc | Loerop James | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 3,853 | 29,085 (0%) | 0% | 1.2 | 4,624 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 01 Feb 2024 | 2,568 | 34,017 (0%) | 0% | 1.2 | 3,082 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 6.80 per share. | 28 Aug 2023 | 14,705 | 21,688 (0%) | 0% | 6.8 | 99,959 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.89 per share. | 08 Feb 2023 | 4,267 | 6,983 (0%) | 0% | 13.9 | 59,272 | Common Stock |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 105,000 | 105,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 11,250 | 33,750 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 11,250 | 11,250 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 155,000 | 155,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | James Loerop | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 3,000 | 3,000 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2021 | 3,000 | 6,323 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.24 per share. | 08 Jul 2021 | 731 | 5,592 (0%) | 0% | 43.2 | 31,608 | Common Stock |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 16,802 | 16,802 | - | - | Stock Option (Right to Buy) | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2021 | 6,705 | 6,705 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 1,567 | 3,133 | - | - | Restricted Stock Unit | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 1,567 | 3,323 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jul 2020 | 3,000 | 3,000 (0%) | 0% | 0 | Common Stock | |
| Anika Therapeutics Inc. | James Loerop | EVP Business Development | Sale of securities on an exchange or to another person at price $ 35.15 per share. | 08 Jul 2020 | 1,244 | 1,756 (0%) | 0% | 35.2 | 43,727 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges